 |
Myriad Genetics to Announce First Fiscal Quarter 2013 Results on Monday, November 5, 2012
Oct 15, 2012
|
12.2 KB |
|
| |
SALT LAKE CITY, Oct. 15, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the first fiscal quarter 2013 following the close of market on Monday, November 5, 2012.
The Company will also host a conference call on Monday, November 5, 2012 at 4:30 P.M. Eastern to review the fi...
|
|
Myriad's HRD Score Detects Loss of DNA Repair Function in Ovarian Cancer
Oct 10, 2012
|
15.3 KB |
|
| |
SALT LAKE CITY, Oct. 10, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a study published in the British Journal of Cancer demonstrated the ability of the Company's Homologous Recombination Deficiency (HRD) Assay to detect loss of DNA repair in ovarian tumors. The study, entitled, "Patterns of Genomic Loss of Hete...
|
|
Myriad Genetics Sponsors Cancer Awareness Initiatives in Support of National Hereditary Breast and Ovarian Cancer Week
Oct 3, 2012
|
16.2 KB |
|
| |
SALT LAKE CITY, Oct. 3, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that, in support of National Hereditary Breast and Ovarian Cancer (HBOC) Week and National Previvor Day, it has launched an online quiz to help people assess their risk for hereditary cancers. The Hereditary Cancer Quiz is available online at www.he...
|
|
Noridian Notifies Myriad of Initial Draft Decision to Classify Prolaris(R) as a Non-Covered Service
Sep 24, 2012
|
15.6 KB |
|
| |
SALT LAKE CITY, Sept. 24, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that Noridian, the Medicare Administrator for Utah, has notified Myriad of its intent to add the Company's prostate prognostic test, Prolaris®, to its next draft Non-Covered Service LCD (local coverage determination). Noridian will solicit pu...
|
|
Myriad Genetics to Present at the Morgan Stanley Global Healthcare Conference
Aug 30, 2012
|
11.5 KB |
|
| |
SALT LAKE CITY, Aug. 30, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the Morgan Stanley Global Healthcare Conference, at 1:00 p.m. Eastern Time on Wednesday, September 12, 2012. The conference is being held at The Grand Hyatt New York in New York, ...
|
|
U.S Court of Appeals Upholds Myriad's Gene Patents
Aug 16, 2012
|
15.8 KB |
|
| |
SALT LAKE CITY, Aug. 16, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) reported today that the United States Court of Appeals for the Federal Circuit declared that the Company's composition of matter claims covering isolated DNA of the BRCA 1 and BRCA 2 genes are patent-eligible material under Section 101 of the United States Patent ...
|
|
Myriad Genetics Reports Fourth Quarter and Fiscal Year 2012 Results
Aug 14, 2012
|
26.4 KB |
|
| |
SALT LAKE CITY, Aug. 14, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its fourth quarter and fiscal year ending June 30, 2012. Revenue for the fourth fiscal quarter increased 24 percent over the same period in the prior year to $133.0 million and resulted in fiscal year 2012 revenue of $496.0 million, an ...
|
|
Myriad Genetics and Pharma Mar Enter Into Companion Diagnostic Agreement
Jul 26, 2012
|
15.7 KB |
|
| |
SALT LAKE CITY, July 26, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has signed an agreement with Pharma Mar, a leader in the development of marine-derived drugs. Under the agreement, Myriad will conduct BRCA 1 and BRCA 2 testing on patients to be enrolled in a Phase II clinical study of PM1183, a novel drug...
|
|
Myriad Genetics to Announce Fiscal Fourth Quarter and Fiscal Year 2012 Results on Tuesday, August 14, 2012
Jul 24, 2012
|
12.3 KB |
|
| |
SALT LAKE CITY, July 24, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the fourth fiscal quarter and fiscal year 2012 following the close of market on Tuesday, August 14, 2012.
The Company will also host a conference call on Tuesday, August 14, 2012 at 4:30 P.M. Eastern...
|
|
Myriad Genetics Receives the Charles R. Smart Visionary Award From the American Cancer Society(R)
Jun 6, 2012
|
14.5 KB |
|
| |
SALT LAKE CITY, June 6, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics announced today that the Company is the honorable recipient of the 2012 Charles R. Smart Visionary Award from the American Cancer Society's Salt Lake City office, a part of the Great West Division. This award is presented annually at the Society's Legacy & Leadership event to recogniz...
|
|
Myriad's Lung Cancer Prognosis Test Shown to Significantly Predict Survival in Early Stage Lung Cancer Patients
Jun 4, 2012
|
15.3 KB |
|
| |
SALT LAKE CITY, June 4, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled "Use of a Proliferation-Based mRNA Signature to Predict Outcome in Early-Stage Non-Small Cell Lung Adenocarcinoma," was presented on Sunday, June 3, 2012 at the American Society of Clinical Oncology® (ASCO) Annual M...
|
|
Myriad Genetics to Present at Upcoming Investor Conferences in June
May 22, 2012
|
11.7 KB |
|
| |
SALT LAKE CITY, May 22, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that the Company is scheduled to present at two upcoming investor conferences:
Jefferies 2012 Global Healthcare Conference in New York City, New York on June 5th at 8:30 a.m. Eastern Time; and
Goldman Sachs 33rd Annual Glob...
|
|
Myriad Genetics Announces Presentation of Lung Cancer Study at American Society for Clinical Oncology Annual Meeting
May 16, 2012
|
15.0 KB |
|
| |
SALT LAKE CITY, May 16, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today the presentation of a study at the American Society of Clinical Oncology® (ASCO) Annual Meeting, including the complete results from a study titled, "Use of a proliferation-based mRNA signature to predict outcome in early-stage non-small cell l...
|
|
Myriad RBM Announces the Launch of OncologyMAP® v. 2.0
May 9, 2012
|
16.3 KB |
|
| |
Salt Lake City, UT (PRWEB) May 09, 2012
Myriad Genetics (NASDAQ: MYGN) announced today that Myriad RBM, a wholly owned subsidiary of Myriad Genetics, has launched OncologyMAP® v. 2.0, a powerful research tool developed with funding and direction from the National Cancer Institute and the Cancer Prevention Research Institute of Texas. Oncolo...
|
|
Myriad Genetics Reports Record Third Fiscal Quarter 2012 Results
May 1, 2012
|
25.4 KB |
|
| |
SALT LAKE CITY, May 1, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced results for its third fiscal quarter and nine months ending March 31, 2012. Revenue for the third fiscal quarter was $129.8 million, an increase of 27 percent over the $102.4 million reported in the third fiscal quarter of 2011. Earnings per diluted ...
|
|
Myriad Genetics to Announce Fiscal 2012 Third Quarter Results on Tuesday, May 1, 2012
Apr 10, 2012
|
12.2 KB |
|
| |
SALT LAKE CITY, April 10, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it will issue financial results for the third fiscal quarter following the close of market on Tuesday, May 1, 2012.
The Company will also host a conference call on Tuesday, May 1, 2012 at 4:30 P.M. Eastern to review the financial resu...
|
|
Myriad Study Finds High Prevalence of Mutations in the PMS2 Gene
Mar 29, 2012
|
15.3 KB |
|
| |
SALT LAKE CITY, March 29, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled, "Representation of PMS2 mutations in patients seeking genetic testing for Lynch syndrome," was presented at the 2012 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting. The study...
|
|
Myriad and Cephalon Enter Into Companion Diagnostic Agreement
Mar 28, 2012
|
15.6 KB |
|
| |
SALT LAKE CITY, March 28, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that it has signed an agreement with Cephalon Inc., a subsidiary of Teva Pharmaceutical Industries Ltd Company, to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in a Phase I/II clinical study.
"We are extremely plea...
|
|
Supreme Court of the United States Remands Gene Patenting Case
Mar 26, 2012
|
17.5 KB |
|
| |
SALT LAKE CITY, March 26, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) reported today that the Supreme Court of the United States remanded the case of The Association for Molecular Pathology, et al., v. Myriad Genetics, Inc., et al (Docket No. 11-725) to the Federal Circuit Court of Appeals. As a result of this decision by the Supre...
|
|
Prolaris(R) Test Awarded Best Poster Honor at 27th Annual EAU Congress in Paris, France
Feb 27, 2012
|
16.2 KB |
|
| |
SALT LAKE CITY, Feb. 27, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that a presentation entitled, "Validation of a panel of cell-cycle progression genes for improved risk-stratification in a contemporary radical prostatectomy cohort," won the best poster honor at the 27th Annual EAU Congress in Paris, France over t...
|
|
|
